

Ref. No.: QHTL/Sec/SE/2019-20/58

31/10/2019

The Manager,  
Corporate Services,  
BSE Limited,  
14<sup>th</sup> Floor, P J Towers, Dalal Street,  
Mumbai – 400 001  
Ref: Security ID: QUICKHEAL  
Security Code: 539678

The Manager,  
Corporate Services,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Symbol: QUICKHEAL  
Series : EQ

Dear Sir/Madam,

Sub: Quick Heal Technologies Ltd to invest in L7 Defense Ltd, Israel

Please find enclosed a release on captioned subject being issued by the Company today.

Further, in terms of Regulation 30(4) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, enclosed are the details of the aforesaid investment.

This is for your information and records.

Yours faithfully,  
For Quick Heal Technologies Limited

  
A. Srinivasa Rao  
Company Secretary



Encl: a/a



## **Quick Heal Technologies Ltd to make Strategic Investment in L7 Defense, Israel based Cybersecurity Startup**

Quick Heal Technologies Limited, one of the leading providers of IT Security and Data Protection Solutions to Consumers, Enterprises and Government announced today that it has signed a definitive agreement to make a strategic investment of USD 300,000 in Israel based L7 Defense. Incorporated in the year 2015 in Tel Aviv, L7 Defense is a cybersecurity startup specializing in Next Generation Web Application Firewall (NG-WAF) and Application Program Interface (API) Security to safeguard businesses against Botnet and Distributed Denial of Service (DDoS) attacks.

This investment will mark Quick Heal's foray into the fast-growing NG-WAF and API Security Market and expand its portfolio of enterprise security solutions under brand 'Seqrite'. At present, Seqrite offers Endpoint Security, Unified Threat Management, Secure Web Gateway, Enterprise Mobility Management, Full Disk Encryption and Data Loss Prevention which are backed by its indigenously developed GoDeep.AI Technology. This relationship will bring together Quick Heal's strong legacy backed by deep intelligence on the threat landscape and L7 Defense's next-generation Ammune™ technology to deliver robust defense against the next wave of AI-driven DDoS cyber-attacks.

According to Quick Heal Security Labs, cybercriminals are increasingly leveraging technologies like Artificial Intelligence and Machine Learning to launch automated botnet and DDoS attacks against enterprises of all sizes. Such attacks are likely to be more accurate and damaging with real-time deployment of AI and comprised network of IoT devices to defeat the traditional defense layers. This is where L7 Defense enters the picture with its Ammune™ Technology that provides advanced protection against the most sophisticated DDoS and Botnet attacks.

**Kailash Katkar, Managing Director and Chief Executive Officer, Quick Heal Technologies Limited,** said *"At Quick Heal Technologies, we are deeply committed to secure the digital journey of our customers by delivering the best-in-class defense against fatal cyber-attacks. This strategic investment will enable us to deliver NG-WAF and API Security to enterprise customers by leveraging L7 Defense's proprietary technology."*

**Yisrael Gross, Co-Founder, L7 Defense** said *"We are delighted to onboard Quick Heal Technologies as a strategic investor. This relationship will help offer together a unique solution for Discovery, Detection and Defense technology to augment customers' security and visibility posture critical cybersecurity foundations."*

### **About Quick Heal Technologies Limited:-**

Quick Heal Technologies Limited is one of the leading providers of IT security software products and solutions to consumers, businesses and Government. Incorporated in 1995 with a registered office in Pune, Quick Heal has a network of over 25,000 channel partners as on 30th June 2019. It conducts sales and marketing activities across India.

Quick Heal's portfolio includes solutions under the widely recognized brand names 'Quick Heal®' and 'Seqrite®' across various operating systems and devices. For more information about the Company, please visit our website [www.quickheal.co.in](http://www.quickheal.co.in)

### **About L7 Defense:**


L7 Defense LTD is an Israeli-based Application and API Security company. It's Ammune™ AI technology autonomously protects inline from a wide range of cyber-attacks, in a very high precision. L7 Ammune™ was recognized among the most promising cyber solutions in the marketplace while the company was recently recognized as a Key innovator company. For more information about L7 Defense LTD, please visit our website <https://www.l7defense.com/>





**Details of Investment – As required under SEBI Regulations**

Sr. No.	Particular	Details
1	Name of the Target entity (size, turnover etc)	L7 Defense Ltd. Revenue of CY 2018 (Jan-Dec) is 60,000 USD
2	Whether acquisition would fall within related party transaction and whether the promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms-length"	No
3	Industry in which the entity being invested/acquired belongs	Cybersecurity
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisitions of target entity, if its business is outside the main line of business of the listed entity)	This investment will mark Quick Heal's foray into the fast-growing NG-WAF and API Security Market and expand its portfolio of enterprise security solutions under brand 'Seqrite'. At present, Seqrite offers Endpoint Security, Unified Threat Management, Secure Web Gateway, Enterprise Mobility Management, Full Disk Encryption and Data Loss Prevention which are backed by its indigenously developed GoDeep.AI Technology. This relationship will bring together Quick Heal's strong legacy backed by deep intelligence on the threat landscape and L7 Defense's next-generation Ammune™ technology to deliver robust defense against the next wave of AI-driven DDoS cyber-attacks.
5	Brief details of any governmental or regulatory approvals required for the acquisition	This will come under automatic route by filing ODI with authorized dealer
6	Indicative time period for completion of the acquisition	2 <sup>nd</sup> week of November 2019
7	Nature of consideration- whether cash consideration or share swap and details of the same	All Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired	300,000 USD
9	Percentage of shareholding/control acquired and /or number of shares acquired	15,927 shares
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation,	L7 Defense is an Israeli-based API Security startup company. It's proprietary Ammune™ AI technology autonomously inline protects



6-2-4

	<p>history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</p>	<p>from cyber-attacks, in a very high precision. L7 Ammune™ is recognized among the most promising cyber solutions in the marketplace while the company was recently recognized as a Key innovator company.</p> <p>L7 was incorporated on May 14, 2015 in Israel. L7 has a subsidiary in Luxembourg.</p> <p><u>Revenue (Fiscal year ended December)</u></p> <p>CY16 - None CY17 - USD 10,000 CY18 - USD 60,000</p>
--	---	--

CA = f

